Podcasts about fadces

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

Join clinical experts Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU, Madhuri M. Vasudevan, MD, MPH, FACE, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, to learn how the AACE Patient Journey of Diabetes Technology supports people with diabetes in navigating their treatment options with confidence. This patient-friendly resource, developed from AACE clinical guidelines and reviewed by Diabetes Sisters, a leading patient advocacy organization, provides clear and accurate information on diabetes technologies, from glucose monitors to insulin delivery devices. The experts also highlight how members of the endocrine care team are using this tool to empower people with diabetes to manage their journey. This episode is brought to you with the support of Abbott, Novo Nordisk, Medtronic, and Vertex.

On this episode of The Huddle, Wendy Mobley-Bukstein, PharmD, BCACP, CDCES, CHWC, NASM-CPT, FAPhA, FADCES and Debbie Hinnen, APN, BC-ADM, CDCES, FAAN discuss the importance of medication persistence, how to talk to clients about starting and staying on diabetes medications, and strategies to help clients stay consistent with their medication taking. This episode was made possible with support from Lilly, A Medicine Company.Learn more about the latest in diabetes technology on danatech: danatech l Diabetes Technology Education for Healthcare ProfessionalsLearn more about the ADCES7 Self-Care Behaviors: Self-Care Tips (ADCES7)References:Kennedy-Martin, T., Boye, K. S., & Peng, X. (2017). Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. Patient Preference and Adherence, 11, 1103–1117. https://doi.org/10.2147/PPA.S136639McGovern, A., Hinton, W., Calderara, S. et al. A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study. Diabetes Ther 9, 229–242 (2018). https://doi.org/10.1007/s13300-017-0361-5Evans M, Engberg S, Faurby M, Fernandes JDDR, Hudson P, Polonsky W. Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. Diabetes Obes Metab. 2022; 24(3): 377-390. doi:10.1111/dom.14603Sabaté E., Adherence to Long-Term Therapies: Evidence for Action, 2003, World Health Organization, Geneva, Switzerland.https://www.ama-assn.org/delivering-care/physician-patient-relationship/8-reasons-patients-dont-take-their-medicationshttps://www.npr.org/sections/health-shots/2017/09/08/549414152/why-do-people-stop-taking-their-meds-cost-is-just-one-reasonhttps://www.adces.org/docs/default-source/handouts/adces7/handout_pwd_adces7_takingmedication.pdf?sfvrsn=4e3f6359_13 Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Video Version Only on HCPLive! In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, co-hosts Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, FADCES, and Natalie Bellini, DNP, FNP-BC, provide a comprehensive review of the 2025 American Association of Clinical Endocrinology (AACE) Annual Meeting held in Orlando, Florida. The episode captures notable sessions, emerging clinical insights, and advances in diabetes care and endocrinology presented during the conference. The discussion opens with reflections on keynote lectures, including a plenary led by Daniel Drucker, MD, on incretin physiology and the clinical evolution of GLP-1 receptor agonists. Isaacs highlights the importance of his translational research and addresses the implications of safety concerns such as pancreatitis and thyroid cancer. Both hosts express admiration for Drucker's role in shaping the field of incretin-based therapies. Another highlight includes the plenary delivered by Anne L. Peters, MD, which emphasized health equity and expanding access to diabetes technology in underserved populations. Isaacs discusses Peters' innovative use of pharmacists in insulin pump clinics and her longstanding contributions to ADA standards of care. Bellini commends Peters' dual impact in both affluent and marginalized communities. The hosts also describe their participation in a hands-on diabetes technology workshop, where attendees rotated through device-specific stations including insulin pumps, CGMs, inhaled insulin, and smart pens. This workshop was part of a broader effort to launch a diabetes technology certification program, with both in-person and online components scheduled for release in summer 2025. Clinical trial updates included coverage of the CONTROL-IQ Plus RCT in type 2 diabetes, studies on weekly insulin formulations, CGM use in inpatient settings, and the Inhale-3 trial on inhaled insulin efficacy. Discussions also touched on advancements in over-the-counter CGMs, data interpretation challenges in individuals without diabetes, and the proposed shift toward using time-in-normal glucose range (TING) metrics to assess glycemic control. The episode concludes with enthusiasm for the future of patient-centered technology and anticipation for the AACE 2026 meeting in Las Vegas. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

This week on The Huddle, we're resharing an episode from last summer featuring Kristine Batty, PHD, APRN, BC-ADM, CDCES, FADCES as she discusses her experience both living with Type 1 diabetes and working with people with diabetes as a certified diabetes care and education specialist. She shares the importance of putting yourself in your client's shoes in order to understand their goals and pain points and support their needs, especially when it comes to diabetes technology.Visit danatech here: danatech l Diabetes Technology Education for Healthcare ProfessionalsLearn more about the latest developments in T1D screening here: T1D ScreeningView Kristine's video series below:https://www.youtube.com/watch?v=HPqraDx-aQwhttps://www.youtube.com/watch?v=SBYpv3LuzBwhttps://www.youtube.com/watch?v=otRUIrx6FkIhttps://www.youtube.com/watch?v=uDrDSSK99-A Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Registration is open now for ADCES25 taking place August 8-11 in Phoenix, AZ! Our conference planning chair Christina Whitehouse, RN, MSN, APRN, ARNP, FADCES, CDCES, shares what to look forward to at this year's conference, and why ADCES' annual conference is the place to be for all diabetes care and education specialists and other professionals in the diabetes space. Register for this year's annual conference at ADCES 2025 Annual MeetingExplore all there is to see in Phoenix at Roosevelt Row Arts District | Downtown Phoenix Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Join endocrine experts Lubaina S. Presswala, DO, FACOI, FACE; Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, FADCES; and Viral N. Shah, MD, FACE, as they explore the latest in continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems for managing diabetes. In this episode, they discuss the practical applications of diabetes technology, patient selection, shared decision-making, and considerations for device use in specific populations, including athletes and pregnant individuals. This conversation provides valuable insights to help clinicians navigate device options and enhance outcomes across diverse patient scenarios.

This week on The Huddle, we're resharing a discussion with current ADCES President, Veronica Brady, PhD, FNP-BC, BC-ADM, CDCES, FADCES. Veronica discussed the concept of unconscious bias, how it shows up in our everyday lives and in working as health care professionals, and how we can practice cultural humility to better serve the needs of people with and at risk for diabetes.  Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

A new episode of Diabetes Day by Day is here! Join Drs. Neil Skolnik and Sara Wettergreen as they dive into the world of mobile health technology and how it's shaping diabetes management. With so many apps for tracking blood glucose (blood sugar), counting carbs, and logging fitness activities, it can be tough to find the right one. In this episode, we welcome Susan Weiner, MS, RDN, CDCES, FADCES, a nutrition, health, and diabetes expert with knowledge of diabetes-related apps, and Bridget Wood, RD, LD, CDCES, who has lived with type 1 diabetes for over 15 years and has firsthand experience with apps that can assist with diabetes management. Our guests will share valuable insights on how apps can support people living with diabetes and why using them can be beneficial. This episode isn't sponsored, and we're not endorsing any specific app—just sharing examples of ones that have helped others. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Susan Weiner, MS, RDN, CDCES, FADCES — Columnist at Endocrine Today, Owner of Susan Weiner Nutrition, PLLC, and Nutrition Communicator and Media Consultant, New York City Metropolitan Area Bridget Wood, RD, LD, CDCES — Owner and Clinical Director of Bridget Wood Wellness, LLC, Reno, NV Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day! For additional resources, be sure to check out: FDA Alert DiabetesWise ADCES Danatech Apps and Platforms Phone apps referenced: Glucose Blood Sugar Tracker Dario Health Livongo by Teladoc Health mySugr Dexcom G7 Tidepool OMRON (for blood pressure)

Eileen Egan, DNP, FNP-C, BC-ADM, CDCES, FADCES joins The Huddle to share her expertise about the interplay between weight and glycemic management in people with Type 2 diabetes, the importance of meeting glycemic and weight goals early after a Type 2 diabetes diagnosis, as well as best practices for helping people stay motivated and engaged. This episode was made possible with support from Lilly, A Medicine Company. Learn more about this topic in this accompanying patient/client handout (support for the development of this handout was provided by Lilly, A Medicine Company): adces_tipsheet_early_control2.pdf References:American Diabetes Association. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes- 2024. Diabetes Care, 47(1): S145-S157.Center for Disease Control and Prevention. Adult overweight and obesity. https://www.cdc.gov/obesity/basics/adult-defining.htmlDCCT/EDIC study research group. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016;39(5):686-693. Gregg E, Jakicic J, Blackburn G, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post hoc analysis of the Look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol. 2016; 4(11): 913-921.Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int J Mol Sci. 2021. 27;22(21):11629.Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia. Endocrinol Metab Clin North Am. 2003;32(4):855-867. Jin X, et al. Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B. 2023;13(6):2403-2424.  Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426.Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.Lancet Diabetes Endocrinol. 2019;7(5):344-355.Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022 Jan 22;399(10322):394-405. doi: 10.1016/S0140-6736(21)01919-X. Epub 2021 Sep 30. Erratum in: Lancet. 2022 Jan 22;399(10322):358. PMID: 34600604Rachel G. Miller, Trevor J. Orchard; Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 1 March 2020; 69 (3): 291–299. https://doi.org/10.2337/db19-0514Ross, R., Neeland, I.J., Yamashita, S. et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol16, 177–189 (2020). https://doi.org/10.1038/s41574-019-0310-7Thom G, McIntosh A, Messow CM, et al. Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT). Diabetes Obes Metab. 2021;(23):711-719.Tsai AG, Bessesen DH. Obesity. Ann Intern Med. 2019;170(5):ITC33-ITC48.Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154.World Health Organization. Obesity. https://www.who.int/health-topics/obesity#tab=tab_1 Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

During a special episode of The Huddle recorded live at our 2024 annual meeting, we sat down with incoming ADCES President Veronica Brady, PhD, FNP-BC, BC-ADM, CDCES, FADCES. Veronica discussed the impact she wants to leave behind as President this coming year, as well as the concept of unconscious bias, how it shows up in our everyday lives and in working as health care professionals, and how we can practice cultural humility to better serve the needs of people with and at risk for diabetes. Please note: since the recording of this episode, Kirsten Yehl has since moved on from ADCES to pursue another professional opportunity. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Send us a message!In this episode Dana interviews Dr. Lacie Peterson, PhD, RDN, BC-ADM, CDCES, FADCES, FAND. Tune into to this episode to hear about Lacie's career path and about Utah State University's Master of Dietetic Administration program!Dr. Lacie Peterson is a is a clinical associate professor and program director for the Master of Dietetics Administration at Utah State University. With a background as a Registered Dietitian, Diabetes Care and Education Specialist, and Board Certified in Advanced Diabetes Management, Lacie brings a wealth of expertise to her role. Lacie's passion shines through her dedication to mentoring students. She goes above and beyond, guiding them to discover their true career aspirations and crafting personalized education plans tailored to their unique interests, lifestyles, and abilities. Specializing in distance education, Lacie thrives on the diverse perspectives her students bring to the program and the profession as a whole. She completed her Master's degree and PhD in Nutrition and Integrative Physiology at the University of Utah. She believes that service to others in the dietetics profession is one of the best things she can do to stay actively engaged in all areas of nutrition and dietetics.  Her interests include cooking delicious food, traveling the world, skiing, SCUBA diving, and spending time with her husband and cats. Learn more about their program here https://drive.google.com/file/d/1V-vkXeZcCvZ1FM_Xre11EuQhyx5Lfcdw/view?usp=sharing

On this episode of The Huddle, we're joined by Lucille Hughes, DNP, MSN/Ed, CDCES, BC-ADM, FADCES, Director of Scientific Communication, Information, and Education at Embecta. Lucille discusses some of the unique care needs to consider when working with people with Type 2 diabetes who take insulin, how the DCES and other members of the diabetes care team can help to address their specific diabetes burdens and struggles, and how care for people with Type 2 diabetes differs from that of Type 1 diabetes.This episode is sponsored by Embecta.Find up-to-date diabetes technology product information, device training, professional education and more on danatech: Diabetes technology for healthcare professionals | Danatech (adces.org)Learn more about Embecta here: Discover Our Diabetes Care Products & Learn About EMBECTA Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Recorded live at ADCES24, we sat down with Jane Jeffrie Seley, DNP, MPH, MSN, GNP, BC-ADM, CDCES, CDTC, FADCES​ to talk about the latest in diabetes technology and what to expect in the coming year, how diabetes technology overall is evolving and changing, and how diabetes technology can more seamlessly be integrated into primary care settings.Please note that this episode was recorded in August and some of the technology and updates discussed in future tense may now be in different stages of development or release. References to specific devices and manufacturers are for educational purposes and do not represent an endorsement from ADCES.Links: Register to view ADCES24 on-demand content: ADCES24 (adcesmeeting.org)Find up-to-date diabetes technology product information, device training, professional education and more on danatech: Diabetes technology for healthcare professionals | Danatech (adces.org)Find your technology competency level and resources to dive deeper with our tech competency tool: Technology Competency Finder| Danatech (adces.org)To learn more about the latest and greatest in diabetes technology, register for our Diabetes Technology Conference: Diabetes Technology Conference 2024 (eventscribe.net)To take a deeper dive into the integration of diabetes technology in primary care by checking out this two-part course developed in partnership with the American Association of Nurse Practitioners (Made possible thanks to a grant from Helmsley Charitable Trust).:Part 1: Integrating Diabetes Technology into Primary Care Part 1: Overview and Clinical Scenarios (0.75 CE/CME)Part 2: Integrating Diabetes Technology into Primary Care Part 2: Interactive Case Studies (1 CE/CME)Learn more about the PANTHER Program: Diabetes Technology. Deciphered. | PANTHER ProgramVisit diatribe: Making Sense of Diabetes | DiaTribeVisit the Medical Professional's Reference website: Prescription & OTC Drug Info | Side Effects, Interactions & Dosages (empr.com)Visit the ADA Consumer Guide: ADA Consumer Guide (diabetes.org)Find resources from DiabetesWise: Home » DiabetesWise Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Team-based care models are crucial in managing complex disease states such as cardio kidney metabolic disease. Learn from guests Melissa Magwire, RN, MSN, CDCES, the Program Director of the Cardiometabolic Center Alliance and Christine Memering, MSN, RN, CDCES, BC-ADM, FADCES, on strategies to overcome barriers and improve patient's health outcomes.Cardiometabolic Center Alliance Homepage https://cardiometabolicalliance.org/Artice: ADA: Screen All With Type 2 Diabetes for Fatty Liver Diseasehttps://www.medscape.com/viewarticle/993715Video: A Patient's introduction Fibroscan from Ohio State Medical Centerhttps://www.youtube.com/watch?v=TXxI4bB_CQYSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week's GameChangers explores the transformative impact of continuous glucose monitors (CGMs) on diabetes care. Discover the latest advancements in CGM technology, current ADA recommendations, and practical tips for patient education. The GameChangerCGM technology is constantly changing. The devices are smaller, more user-friendly, and easier to integrate into daily life, thereby improving patient adherence and outcomes. HostJen Moulton, BSPharmPresident, CEimpactGuestJennifer Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADMClinical Professor and Director of Pharmacy EducationUniversity of South Carolina College of PharmacyReferenceADA Info on CGMsAACE Guidelines Update on CGMs Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE InformationLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the principles and applications of continuous glucose monitors (CGMs) and summarize current recommendations for their use in diabetes management.2. Discuss how to educate patients on CGM use, including device placement, data interpretation, and troubleshooting common issues.0.05 CEU/0.5 HrUAN: 0107-0000-24-189-H01-PInitial release date: 06/10/2024Expiration date: 06/10/2025Additional CPE details can be found here.Interested in additional Diabetes and CGM pharmacy education?Guardian of the Glucose Galaxy: The Rise of CGMsDuring this 1-hour CE, we will cover hot topics such as:The evolution of Continuous Glucose Monitors (CGMs)The impact of CGMs in improving health, clinical outcomes, and quality of life for persons with diabetesThe use of CGMs to manage diabetes across patient populationsThe role of pharmacy teams in managing people with diabetesThe opportunity to integrate CGM devices into practicePharmacists Enroll HerePharmacy and Continuous Glucose Monitoring: The Sweetest Pairing [Pharmacist]This 6.5-hour advanced training includes six comprehensive modules designed to equip pharmacists with essential skills and knowledge to successfully integrate CGM services into their pharmacy. Content includes an in-depth understanding of CGM technology and its benefits, ways to tailor management of suitable candidates for CGM use, practical steps for integrating a CGM service into pharmacy practice, tools and techniques for managing CGM patients remotely, and how CGMs can monitor the impact of nutrition, weight management, physical activity, and wellness activities. Pharmacists will be empowered to develop a sustainable service to improve health outcomes for patients with and without diabetes. Pharmacists Enroll Here

This week's GameChangers explores the transformative impact of continuous glucose monitors (CGMs) on diabetes care. Discover the latest advancements in CGM technology, current ADA recommendations, and practical tips for patient education. The GameChangerCGM technology is constantly changing. The devices are smaller, more user-friendly, and easier to integrate into daily life, thereby improving patient adherence and outcomes. GuestJennifer Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADMClinical Professor and Director of Pharmacy EducationUniversity of South Carolina College of Pharmacy ReferenceADA Info on CGMsAACE Guidelines Update on CGMs Interested in additional Diabetes and CGM pharmacy education?Save the date and join us – June 13 @ 7pmCT – registration details below!During this 1-hour Live CGM CE, we will cover hot topics such as:The evolution of Continuous Glucose Monitors (CGMs)The impact of CGMs in improving health, clinical outcomes, and quality of life for persons with diabetesThe use of CGMs to manage diabetes across patient populationsThe role of pharmacy teams in managing people with diabetesThe opportunity to integrate CGM devices into practiceExcited to see you next week!Pharmacists Enroll HereTechnicians Enroll HerePharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the principles and applications of continuous glucose monitors (CGMs) and summarize current recommendations for their use in diabetes management.2. Discuss how to educate patients on CGM use, including device placement, data interpretation, and troubleshooting common issues.0.05 CEU/0.5 HrUAN: 0107-0000-24-189-H01-PInitial release date: 06/10/2024Expiration date: 06/10/2025Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Registration for ADCES24 is now open! Each year, ADCES' annual conference brings together thousands of professionals in the diabetes care space, and this year's event is not one to miss! Conference chair Lisa Hodgson, RD, CDN, CDCES, FADCES joins The Huddle to share all of the exciting sessions and events to look forward to this year in New Orleans.  Learn more and register at ADCES24 (adcesmeeting.org) Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Listen to Katherine R. Tuttle, MD, FASN, FACP, FNKF, Anthony Good, DNP, MBA, FNP-BC, GNP-BC, and Joshua J. Neumiller, PharmD, CDCES, FASCP, FADCES discuss the prevalence of heart failure, chronic kidney disease, type 2 diabetes, and the impact these conditions have on patient outcomes. Management options to mitigate these risks, current guidelines and diagnostic practices will also be discussed.

Special guest Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM,  Clinical Professor and Director of Pharmacy Education from the University of South Carolina College of Pharmacy joins us to talk about meds for obesity and weight loss.Listen in as they discuss management of overweight and obesity, including the role of newer injectable medications, oral options, and lifestyle changes.You'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLM, Clinical Assistant Professor of Family Medicine, Prisma Health/USC-SOMG Family Medicine Residency Program at the USC School of Medicine GreenvilleAndrea Darby Stewart, MD, Associate Director, Honor Health Family Medicine Residency Program and Clinical Professor of Family, Community & Occupational Medicine at the University of Arizona College of Medicine - PhoenixCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Clements reports relevant financial relationships [GLP-1 agonists] with Eli Lilly, Novo Nordisk (speakers bureau).TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.The clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter and Prescriber Insights: Chart: Weight Loss ProductsToolbox: Weight Loss: Helping Your Overweight and Obese PatientsIf you're not yet a Pharmacist's Letter or Prescriber Insights subscriber, find out more about our product offerings at trchealthcare.com. Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

The Co-authors of Divabetic's ebook, "Sweet Romance: A Woman's Guide To Love & Intimacy With Diabetes," Dr. Janis Roszler PhD, LMFT, CDCES, LD/N, FAND, and Donna Rice MBA, BSN, RN, CDCES, FADCES offer advice on discussing your diabetes diagnosis as well as issues related to intimacy, fertility, and menopause with the people you care about the most.  Living with diabetes can be a challenging experience, especially when it comes to your relationships. That's why it's important to talk to your loved ones about your diabetes diagnosis and how it affects your life. It can help you surround yourself with a more supportive and encouraging environment. To help us better understand your unique experiences and struggles with diabetes, the national nonprofits Divabetic and Diabetes Sisters are partnering on the first-ever survey for women with diabetes on love and relationships. This survey, titled "Love Across All Life Stages of Diabetes," allows you to share your thoughts and experiences with us so we can create more meaningful programming and resources to serve you. Please take a few moments out of your day to participate in this survey. Your input can make a difference in the lives of other women living with diabetes. Visit Divabetic.Org and DiabetesSisters.Org Divabetic's ebook, "Sweet Romance: A Woman's Guide To Love & Intimacy With Diabetes," is available at Amazon.

Live at ADCES23, ADCES Immediate Past President Lucille Hughes, DNP, MSN/Ed, CDCES, BC-ADM, FADCES joined The Huddle to introduce ADCES's new strategic plan, and to explain the importance of community involvement and knowing your worth when it comes to diabetes care and education.View ADCES' full 2024-2028 full strategic plan here: adces-strategic-plan.pdf (sitefinity.cloud)Learn more about the plan in this series of blogs: Advance the Expertise of the DCES: A Core Goal of the 2024-28 ADCES Strategic PlanStrategic Plan Goal #1: Improve Access to Diabetes Care and Education: A Strategic Focus for 2024 and Beyond (adces.org)Growing and Diversifying ADCES Membership: A Longstanding Domain in Strategic Priorities Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle/podcast. Learn more about ADCES and the many benefits of membership at adces.org.

Join clinical experts David Lieb, MD, FACE, Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, and Vin Tangpricha, MD, PhD, FACE, as they discuss the 2022 AACE diabetes guideline updates and address the issue, “How Should Hypoglycemia Be Managed?” Key topics include how to put the guideline into practice particularly in primary care settings, how to characterize which people with diabetes should be prescribed glucagon to manage low blood sugar levels, and how to incorporate ready-to-use glucagon into hypoglycemia treatment plans for people with diabetes. Support for this podcast is provided by Xeris Pharmaceuticals, Inc.

Join episode host, Todd Eury (founder and CEO of Pharmacy Podcast Network), as he discusses the indispensable role of pharmacists in T2D care with Diana Isaacs (endocrine clinical pharmacist), and Rohit Moghe (ambulatory care & and population health clinical pharmacist). These pharmacist experts will share insights on why the role of pharmacists is so important in T2D care, including reviewing data on how pharmacist involvement improves measurable outcomes for patients with T2D. To raise awareness, they will also review T2D treatment recommendations from major medical societies. Todd Eury, BS, Rohit Moghe, PharmD, MSPH, CDCES Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP  

The available novel diabetes therapies and their impact on cardiovascular and cardiometabolic risk reduction are discussed by guests Chris Memering, MSN, RN, CDCES, BC-ADM, FADCES, and Sun Kim, MD. A particular emphasis on GLP-1 receptor agonists, and the patients for whom they are guideline recommended, as well as ongoing research are also covered.CE LINK: pcna.net/podcast/novel-diabetes-therapies-in-cvd-risk-reductionGLP-1 RAs: An updated reivew of head-to-head clinical studies: https://pubmed.ncbi.nlm.nih.gov/33767808/ GLP1-RAs: CV benefts & mechanisms of action (Ussher & Drucker): https://pubmed.ncbi.nlm.nih.gov/36977782/ GLP-1 & Underlying Beneficial Actions in Alzheimer's disease, Hypertension, & NASH: ttps://pubmed.ncbi.nlm.nih.gov/34552561/Incretins & microvascular complications of diabetes: https://pubmed.ncbi.nlm.nih.gov/37597048/ Management of Type 2 Diabetes 2022. A Consensus Report by ADA, EASD. doi: 10.2337/dci22-0034.ADA Standards of Care in Diabetes 2023. https://diabetesjournals.org/care/issue/46/Supplement_1AACE Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm--2023 Update. https://www.endocrinepractice.org/article/S1530-891X(23)00034-4/fulltextCardio-renal-metabolic connection: a review of the Evidence. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391899/pdf/12933_2023_Article_1937.pdf See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Guests Gwen Klinkner, DNP, RN, BC-ADM, CDCES, FADCES, and Melissa Magwire, RN, MSN, CDCES describe how to help patients with diabetes navigate behavior change principles to achieve glucose management including nutrition and exercise. They also examine pharmacotherapies for weight loss with glucose-lowering medications.CE Link: pcna.net/podcast/euglycemiaSURMOUNT Trials: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 ADCES: https://www.diabeteseducator.org/PNCA.net AHA.org Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: doi: 10.1136/bmj.321.7258.405Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: AHA Scientific Statement: doi:10.1161/CIR.0000000000001040Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the ADA, ADCES, AND, AAFP, AAPA, AANP, APhA: doi:10.1177/0145721720930959See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join us for a candid discussion on how vaccines can lead to healthier outcomes for people living with diabetes. Our panelists will discuss the value of vaccines in communities of color, which vaccines are most effective in living well for those with diabetes, and how our community partners and advocacy organizations are a catalyst to promoting the value of vaccination. Moderator Anna Norton, MS President, Center for Sustainable Health Care Quality & Equity, National Minority Quality Forum Anna Norton has worked in the non-profit sector for 25 years as an advocate, fundraiser, speaker, and leader. She has been featured in an assortment of health-related magazines and books, including Balancing Pregnancy with Pre-Existing Diabetes, A Woman's Guide to Diabetes: A Path to Wellness and Diabetic Living. Anna graduated with a Bachelor of Science from the University of Florida and Master of Science in Education at Florida International University. Panelists Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP Endocrinology Clinical Pharmacy Specialist Cleveland Clinic Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP is an Endocrinology Clinical Pharmacy Specialist. She serves as the Co-Director of Endocrine Disorders in Pregnancy and the Director of Education and Training in Diabetes Technology at the Cleveland Clinic Endocrinology and Metabolism Institute. Dr. Isaacs earned her bachelor's degree in chemistry from the University of Illinois at Chicago, Doctor of Pharmacy Degree from Southern Illinois University Edwardsville (SIUE) and completed a pharmacy practice residency at the Philadelphia Veterans Affairs. Dr. Isaacs holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management. She served on the American Diabetes Association (ADA) Professional Practice Committee from 2020-2023, the committee that updates the ADA Standards of Care. She is a National Board Member of the Association of Diabetes Care and Education Specialists (ADCES). Tasha Berry-Lewis Health Ministry Director New Spiritual Light Missionary Baptist Church Tasha R. Berry-Lewis is a Health Advocate based in the Chicagoland area. She brings a wealth of experience from her previous role in the federal government, where she specialized in Human Resources, focusing on Labor and Employee Relations, Benefits, Training, and Payroll. Tasha is also a distinguished 20-year military veteran, serving during the Gulf War in Dharan, Saudi Arabia. Since 2021, Tasha has been a part of the National Minority Quality Forum - Faith Health Alliance, where she has been providing educational services to churches in the Chicagoland area on various health-related topics, including influenza, and COVID-19 vaccines. Kristian Hurley Senior Vice President of Programs, Advocacy and Health Equity, Beyond Type 1 Kristian Hurley is the Senior Vice President of Programs, Advocacy, and Health Equity at Beyond Type 1, a global nonprofit that helps people living with diabetes to stay alive and thrive. She is an experienced leader with a history of tripling health impact and revenue by inspiring transformative change in communities through building coalitions to increase health equity. Dr. Enrique Caballero, MD Endocrinologist/Investigator, Division of Endocrinology Diabetes and Hypertension, Division of Global Health Equity, Brigham and Women's Hospital Dr. Caballero is an Endocrinologist, Clinical Investigator and Educator. He is the Faculty Director of International Innovation Programs and Faculty Director of Diabetes Education in the Office for External Education at Harvard Medical School. Dr. Caballero founded the Latino Diabetes Initiative at the Joslin Diabetes Center and the Diabetes Program within the Spanish Clinic at the Brigham and Women's Hospital, both affiliated with Harvard Medical School. He is currently Associate Scientist in the Division of Global Health Equity at the Brigham and Women's Hospital in Boston.

Hat Designer Evetta Petty's motto is"I can design out of anything!" On the eve of her 30th Year Retrospective Fashion Show during New York Fashion Week, Evetta talks with Mr. Divabetic about managing type 2 diabetes in style! For over 30 years, Evetta has designed hats in her uptown New York studio, Harlem's Heaven Hat Shop. Her hats have captured worldwide attention and have been worn to the Kentucky Derby and Royal Ascot in England, on celebrities such as Patti LaBelle and Star Jones, and featured in movies, fashion magazine covers, and editorials such as Essence, Jet, and Italian Vogue Mujer Unica, Vibe, and The New York Times.  Approximately 96 million American adults—more than 1 in 3—have prediabetes. Did you know that over 80% don't know they have it? Prediabetes increases your risk of developing type 2 diabetes, heart disease, and stroke. Light the Way! Join Divabetic's Blue Candle initiative and encourage your friends, co-workers, and family members to be screened for pre-diabetes. The Centers for Disease Control (CDC) offers a quick, easy online Pre-Diabetes risk test (https://www.cdc.gov/prediabetes/risktest/index.html). Be by their side when they check, and share your successes and struggles of living with diabetes so they can see that living well with diabetes is possible. Divabetic's first e-book, Sweet Romance: A Woman's Guide to Love and Intimacy with Diabetes, by co-authors Dr. Janis Roszler PhD, LMFT, RDN, CDCES, FAND, and Donna Rice MBA, BSN, RN, CDCES, FADCES, is available on Kindle.

In this episode, Lisa Jones interviews Jennifer Smith, RD, LD, CDCES, and Susan Weiner, MS, RDN, CDN, CDCES, FADCES, about ways to become familiar with diabetes technology, including continuous glucose monitors, insulin pumps, and smartphone applications. This is episode 4 of a 4-part series.

In this episode, Lisa Jones interviews Jennifer Smith, RD, LD, CDCES, and Susan Weiner, MS, RDN, CDN, CDCES, FADCES, about diabetes technology, including smartphone applications, and making recommendations to clients and patients to fit their individual needs. This is episode 1 of a 4-part series.

In this episode, Lisa Jones interviews Jennifer Smith, RD, LD, CDCES, and Susan Weiner, MS, RDN, CDN, CDCES, FADCES, about emerging technological advances shaping the management of patients with diabetes, education, and fitting a client or patient's needs using technology. This is episode 2 of a 4-part series.

In this episode, Lisa Jones interviews Jennifer Smith, RD, LD, CDCES, and Susan Weiner, MS, RDN, CDN, CDCES, FADCES, about the benefits and pitfalls of diabetes technology, including ways to overcome challenges. This is episode 3 of a 4-part series.

This week we sat down with Dr. Lacie Peterson, PhD, RDN, BC-ADM, CDCES, FADCES, FAND, Director of Utah State's Master of Dietetics Administration and Dietetic Internship program which allows you to complete your graduate degree AND supervised practice rotations in an online/distance format. Gain insight into this incredibly affordable program, advice for applicants, and who is best fit for the program. For more information, visit their website here: https://caas.usu.edu/mda/

For the past 64 years. Barbie has been a part of our lives, a cultural touchstone, or the quintessential image of what a woman should be but never will be - a sex or beauty object. Greta Gerwig's big-screen Barbie makeover and the related marketing blitz are inspiring us revisit and reevaluate Barbie and Ken's impact on our lives, including our sex lives. After all, if Barbie and Ken are confused about what to do at sleepovers, you might be too, especially if you're dealing with sexual health issues related to diabetes. Diabetes is one of the most common chronic diseases in nearly all countries. People with diabetes experience sexual dysfunction more often than the general public. Podcast guests: Dr. Janis Roszler PhD, LMFT, RDN, LD/N, CDCES, FAND, and Donna Rice, MBA, BSN, RN, CDCES, FADCES, the co-authors of Divabetic's new e-book, Sweet Romance: A Woman's Guide to Love and Intimacy with Diabetes, available on Amazon.  Dr. Janis Roszler and Donna Rice use humor, helpful examples, and insightful questions to present key topics about sexual health in an engaging, approachable way in the e-book Sweet Romance: A Woman's Guide to Love and Intimacy with Diabetes. This first ebook in the series is perfect for anyone (regardless of gender, sexual orientation, age, or health status) looking to rekindle intimacy with their partner or be proactive about their sexual and emotional well-being.   Barbie & Ken Podcast Music by Doug Clay.

    Susan Weiner SPEAKER | AUTHOR MS | RDN | CDCES | FADCES Susan Weiner is an award-winning nutrition, health and diabetes expert and the owner of Susan Weiner Nutrition, PLLC. Susan served as the 2015 ADCES Diabetes Educator of the Year and is an ADCES fellow. Among her many distinguished awards, she is the recipient of the 2019 Metropolitan New York Association of Diabetes Educators Advocate of the Year Award and the 2018 Media Excellence Award from the New York State Academy of Nutrition and Dietetics. Susan is the “Diabetes in Real Life” columnist for Endocrine Today and is the on-air host for video interviews and content for Healio.com. She is the co-author of The Complete Diabetes Organizer: Your Guide to a Less Stressful and More Manageable Diabetes Life and Diabetes: 365 Tips for Living Well. Susan has extensive TV, radio, podcast and video experience and is well versed in media communications. Susan is a well-respected national and international speaker on a variety of topics related to nutrition, diabetes, wellness and health, and has authored dozens of articles in peer reviewed journals. She has authored and been cited in over 300 articles for popular press, consumer publications and online sites. Susan earned her Master's Degree in Applied Physiology and Nutrition from Columbia University. Susan Weiner, MS RDN CDCES FADCES Owner and Clinical Director, Susan Weiner Nutrition PLLC 2015 ADCES Diabetes Educator of the Year Diabetes In Real Life columnist, Endocrine Today New Website! www.susanweinernutrition.com - @susangweiner     The Happy Diabetic Kitchen Podcast is sponsored by US MED Please visit https://www.usmed.com/happydiabetic/ today for a free benefits check   US MED WELCOMES THE HAPPY DIABETIC COMMUNITY When it comes to your health, nothing else matters. That's why with US MED, your health matters to us. From insulin pumps, continuous glucose monitors, blood glucose strips and more, your well-being is in the right hands with the experts at US MED. Call Us : 888-885-0012  

In this week's episode, we spoke with Mandy Reece, PharmD, CDCES, BC-ADM, BCACP, FADCES, vice chair and associate professor in the department of pharmacy practice at Philadelphia College of Osteopathic Medicine, on diabetes care, change in treatment, and management.

Teresa Pearson, MBA, MS, RN, CDCES, FADCES, joins us to talk about population health. She shares her early experience with population health. As you'll hear, this model of care can greatly reduce total cost of care and improve health outcomes for people with diabetes. It's a solid approach to demonstrate the value you bring to the diabetes care team, so make sure to listen to the entire episode to get actionable tips on information technology, data and reporting you can start implementing quickly.Resources:ADCES population health resources: DiabetesEducator.org/PopulationHealthADCES Value Toolkit: DiabetesEducator.org/ValueADCES Annual Conference information: ADCESmeeting.org

The National Practice Survey is conducted once every 5 years to help ADCES understand current trends in the diabetes care and education specialist workforce and how their services are integrated into the full care team. 2022 ADCES President Jan Kavookjian, PhD, MBA, FAPhA, FADCES, joins us to discuss why this survey is so important. She gives us a teaser of some of this year's findings and explains how the results influence strategic planning and key initiatives at the association. ADCES gratefully acknowledges Joanne Rinker, MS, RDN, CDCES, LND, FADCES, Sheryl Traficano and the Certification Board for Diabetes Care and Education, the National Practice Survey writing group and any others involved for their support of the National Practice Survey.ResourcesKavookjian J, Bzowyckyj AS, DiNardo MM, et al. Current and Emerging Trends in Diabetes Care and Education: 2021 National Practice and Workforce Survey. The Science of Diabetes Self-Management and Care. 2022;48(5):307-323. doi:10.1177/26350106221120787ADCES Blog Post: Key Takeaways from Current and Emerging Trends in Diabetes Care & Education: 2021 National Practice and Workforce Survey: www.diabeteseducator.org/news/perspectives/adces-blog-details/adces-perspectives-on-diabetes-care/2022/10/10/key-takeaways-from-current-and-emerging-trends-in-diabetes-care-education-2021-national-practice-and-workforce-surveyValue of the DCES Toolkit: www.DiabetesEducator.org/ValueAsk the Reimbursement Expert: www.diabeteseducator.org/practice/ask-the-expert

Eva Vivian, PharmD, PhD, BC-ADM, CDCES, FADCES, and Daphne Smith Marsh, PharmD, BC-ADM, CDCES, discuss the impact of health disparities on-site at ADCES22 in Baltimore. You'll hear their perspectives on the environmental and social factors that contribute to health disparities, both in and out of the clinical setting. You'll also hear how diabetes care and education specialists and other healthcare professionals can address health disparities in simple, practical ways that meet the needs of the individual while building trust.Resources:ADCES Resources on Health Equity: DiabetesEducator.org/HealthEquityADCES22 On-Demand Sessions: ADCES22.orgEdgoose J, Quiogue M, Sidhar K. How to Identify, Understand, and Unlearn Implicit Bias in Patent Care. Fam Pract Management. 2019 Jul-Aug;26(4):29-33Reid H, Lin O, Fabbro RL, et al. Provider communication in black patients with T2DM is associated with glycemic control. Presented at: American Diabetes Association 80th Scientific Sessions; June 12-16, 2020. Abstract 52-LB.Akturk HK, Agarwal S, Hoffecker L, Shah VN. Inequity in racial ethnic representation in randomized controlled trials of diabetes technologies in type 1 diabetes: critical need for new standards. Diabetes Care. 2021;44(6):e121-e123.

Dr Jane Jeffrie Seley, MPH, MSN, NP, RN, APRN, BC-ADM, CDCES, FADCES, brings us the top highlights from the technology seen at the ADCES22 conference in Baltimore this year. She's talking about what's new and what's next in CGM, BGM, insulin delivery, connected devices, and more.  Jane references specific of devices and manufacturers here, but keep in mind that these references are for educational purposes and do not represent an endorsement from ADCES.Show NotesADCES22 sessions on demand: ADCES22.orgLearn more about the latest diabetes technology: Danatech.org 

Michelle Litchman, PhD, FNP-BC, FAANP, FADCES, FAAN is an Assistant Professor at the University of Utah College of Nursing, Adjunct Assistant Professor of Internal Medicine, and Nurse Practitioner at the Utah Diabetes and Endocrinology Center. She serves as the Medical Director of the Intensive Diabetes Education and Support Program at the University of Utah, a multidisciplinary diabetes self-management education and support program that integrates shared medical visits. Her NIH and foundation-funded program of research is in the nexus between diabetes, digital health, and health disparities. Her research has three overarching foci: 1) the social context of diabetes management in online (peer support communities) and family (romantic partners, parents) environments, 2) technology mediated diabetes interventions to address health disparities with an emphasis on Deaf, Hispanic, and rural communities; and 3) novel methods to examine real-world diabetes self-management. Her research focused on the underground exchange (donating, trading, borrowing, and purchasing) of diabetes medications and supplies was highlighted across national media outlets, including NPR Science Friday, CNN, and The Doctors. Dr. Litchman has worked closely with legislators and national professional organizations, where her research has influenced policies and practice. Dr. Litchman received her research doctorate and master's degree from the University of Utah and undergraduate degree from Weber State University. Dr. Litchman is a Jonas Scholar, Betty Irene Moore Nurse Leader and Innovation Fellow, and University of Utah Presidential Societal Impact Scholar. She has been inducted as a Fellow of the American Association of Nurse Practitioners, Association of Diabetes Care and Education Specialist, and American Academy of Nursing.

We're celebrating Divabetic's 12th Year Anniversary of Podcasting with musical inspiration from Babyface and music from his A Closer Look album courtesy of SONY Music. Guests include Poet Lorraine Brooks,Susan WeinerMS, RDN, CDCES,FADCES, Ivan Hampden Jr., and Collage Artist Tom Cocotos. Hosted by Max "Mr. Divabetic" Szadek.  Our musical inspiration, Kenneth Edmonds who is known professionally as Babyface, has written over 250 top-10 R&B and pop hits, working with the likes of Beyoncé, Aretha Franklin, Celine Dion, Luther Vandross, and Whitney Houston. "The blessing of being able to write music and let music speak for itself is you let the melodies and let the lyrics and the groove talk to people instead of me talking to people," says Babyface.  What makes Babyface so great? His ability to craft a song that touches our emotions captivates our ears and aligns every word in perfect harmony. It's a rare gift that not many people have in music. "I would say that I've been lucky. Being blessed and not really ever giving up," says Babyface. Thank you for allowing us to be part of your diabetes wellness journey! We're looking forward to sharing more insight and advice on diabetes self-care from experts and peers, along with more great music in the next year!

Join us as we welcome Dr. Susan Cornell, PharmD, CDCES, FAPhA, FADCES, an associate director of experiential education and professor in the department of pharmacy practice at Midwestern University College of Pharmacy. Dr. Cornell provides insight into ADCES, its benefits, and obtaining credentials as a practicing pharmacist interested in diabetes care. Pharmacists are only a small portion of diabetes educators and obtaining credentialing can provide more opportunities. Listen in to learn about ways you can get involved from an esteemed pharmacist with over 25 years of experience in diabetes management. Learn more about your ad choices. Visit megaphone.fm/adchoices

Join us as we welcome Dr. Susan Cornell, PharmD, CDCES, FAPhA, FADCES, an associate director of experiential education and professor in the department of pharmacy practice at Midwestern University College of Pharmacy. Dr. Cornell provides insight into ADCES, its benefits, and obtaining credentials as a practicing pharmacist interested in diabetes care. Pharmacists are only a small portion of diabetes educators and obtaining credentialing can provide more opportunities. Listen in to learn about ways you can get involved from an esteemed pharmacist with over 25 years of experience in diabetes management. Learn more about your ad choices. Visit megaphone.fm/adchoices

Join us as we welcome Dr. Susan Cornell, PharmD, CDCES, FAPhA, FADCES, an associate director of experiential education and professor in the department of pharmacy practice at Midwestern University College of Pharmacy. Dr. Cornell provides insight into ADCES, its benefits, and obtaining credentials as a practicing pharmacist interested in diabetes care. Pharmacists are only a small portion of diabetes educators and obtaining credentialing can provide more opportunities. Listen in to learn about ways you can get involved from an esteemed pharmacist with over 25 years of experience in diabetes management. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, and Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, discuss the use of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes, including:Overview of chronic kidney diseaseGuideline recommendationsEvidence for finerenoneRole of the pharmacistPresenter:Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCPEndocrine Clinical Pharmacy SpecialistCGM and Remote Monitoring Program CoordinatorEndocrinology and Metabolism InstituteCleveland ClinicCleveland, OhioJoshua J. Neumiller, PharmD, CDCES, FADCES, FASCPVice Chair and Allen I. White Distinguished ProfessorDepartment of PharmacotherapyCollege of Pharmacy and Pharmaceutical Sciences  Washington State UniversitySpokane, WashingtonReview the downloadable slideset and the full program at:https://bit.ly/3wxNAod

In this special edition ATTD Recap episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, provide insight into their favorite sessions from the conference and clinical pearls they took away from their experience, including latest updates in the world of diabetes smart phone apps, smart insulin pens, and CGM systems. Also in the episode, our hosts react to Eli Lilly and Company's announcement of topline data from the SURMOUNT-1 trial in late April. 

The inaugural episode of Diabetes Dialogue features an introduction to hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, and a discussion around recent regulatory news surrounding CGM devices in the US and Europe.  

Words have the power to elevate or tear down someone's perception of themselves and their diabetes health.  For decades, much of the language around diabetes has been focused on adverse outcomes and laden with judgment and blame without considering individual needs, beliefs, and choices. On the other hand, encouraging and collaborative messages can enhance health outcomes.  In 1992, Prince changed his name to an unpronounceable, infamous "Love Symbol." He wrote: "It's all about thinking in new ways, tuning in 2 a new free-quency." It derives from a combination of the symbols for both males and females.  He adopted the symbol as a tool for contract negotiations with his record label. According to Rolling Stone, Warner Bros. wanted Prince to slow down the pace of releasing new music for fear of flooding the market. Unwilling to consent to their request, Prince actually increased his rate.  The Love Symbol meant so much to him that he continued to use it long after changing his stage name back to Prince when his contract with Warner Bros. finally expired.  Guests include Poet Lorraine Brooks, and Susan Weiner MS, RDN, CDCES, FADCES. Throughout the podcast, we will be featuring music from Prince & The New Power Generation's Love Symbol album courtesy of SONY Music. 

Charles D. Ponte, BSc, PharmD, FADCES, FAPhA, FASHP, FCCP, FNAP, and Professor of Clinical Pharmacy and Family Medicine at West Virginia University discusses diabetes and pain management on the PQS Quality Corner Show.Host PQS Associate Director of Pharmacy Accounts of Pharmacy Accounts, Nick Dorich, PharmD asks Ponte about pain and discomfort for patients with diabetes, and Ponte talks specifically about neuropathic pain management.Pharmacist's Letter is offering CE credit for this podcast. Please log into your Pharmacist's Letter account and look for the title of this podcast in the list of available CE courses.

PQS Associate Director of Pharmacy Accounts, Nick Dorich, PharmD,  talks with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, CGM and Remote Monitoring Program Coordinator at the Cleveland Clinic Endocrinology & Metabolism Institute about continuous glucose monitoring.Isaacs defines continuous glucose monitoring (CGM) on the Quality Corner Show and explains the difference between personal versus professional continuous glucose monitoring. Isaacs also explains how pharmacists can be involved with CGM management.Pharmacist's Letter is offering CE credit for this podcast. Please log into your Pharmacist's Letter account and look for the title of this podcast in the list of available CE courses.

People newly diagnosed and living with chronic conditions increasingly turn to technology, the internet and social media seeking information and education, to share clinical information and the latest research, to receive and provide support, and to share solutions and resources. In the spirit of “meeting people where they are,” clinicians are following and joining patients in these social spaces, learning a lot -- and together -- are improving health. In this episode we hear how Nurse Practitioner Michelle Litchman, PhD, FNP-BC, FAANP, FADCES, FAAN practices and innovates at the intersection of diabetes, digital health, and disparities. Searching digital spaces, online resources and communities she discovers the specific needs and pain points that patients and families are experiencing. Her work to better assess and address the many dimensions of access and accessibility led to an awareness and understanding of why people with diabetes are foregoing basic needs and taking part in "life exchanges'' of trading of insulin and medical supplies just to stay healthy, and to the subsequent passage of legislation offering an important lifeline to those who depend on insulin to survive. In her research and innovation, she shares the value of collaborating with citizen scientists so the patients' story and experience are reflected in the research, policies, and solutions. Email us at hello@seeyounowpodcast.com. For additional resources, visit our website at www.seeyounowpodcast.com.

Resources:Share the barriers you identified and how you resolved them through the ADCES Technology Community of Interest:  www.adcesconnect.org/technology-coiMacLeod, J., Scher, L., Greenwood, D., Isaacs, D., Albanese-O'Neill, A., O'Neill, M. S., Golden, L., & Scalzo, P. (2021). Technology Disparities and Therapeutic Inertia: A Call to Action for the Diabetes Care and Education Specialist. ADCES in Practice, 9(5), 34–41. https://doi.org/10.1177/2633559X211032227Utilizing A Technology Framework to Reduce Disparities and Therapeutic Inertia, from the ADCES blog:  https://www.diabeteseducator.org/news/perspectives/aade-blog-details/adces-perspectives-on-diabetes-care/2021/09/28/utilizing-a-technology-framework-to-reduce-disparities-and-therapeutic-inertia.Thank you to the practice paper authors Janice MacLeod, MA, RD, CDCES, FADCES, LaurieAnn Scher, MS, RD, CDCES, Deborah Greenwood, PhD, RN, BC-ADM, CDCES, FADCES, Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, Anastasia Albanese-O'Neill, PhD, APRN, CDCES, Megan S. O'Neill, PA-C, CDCES, Lisa Golden, MA, ED, HD, CRC, CDCES, and Patty Scalzo, MSN, NP, RN, CDCES.

Continuous Glucose Monitoring:Understanding the Pharmacist's Role in Patient Education and Improving Outcomes in Diabetes Management   Objectives  Describe the use of continuous glucose monitoring (CGM) in diabetes management and ADA/AACE recommendations Recognize the role of the pharmacist in providing education related to the use of CGM devices and interpreting CGM data Faculty Disclosures Curtis L. Triplitt, PharmD, has the following relevant financial relationships with commercial interests to disclose: Consultant: Bayer Speaker's Bureau: Eli Lilly, NovoNordisk Susan Cornell, PharmD, CDCES, FAPhA, FADCES, has the following relevant financial relationships with commercial interests to disclose: Speaker's Bureau: Novo Nordisk, Inc. Other Support: Advanced Practitioner Advisory Board- Novo Nordisk, Inc. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for .5 contact hours of knowledge-based credit. This activity is supported by an independent educational grant from Abbott Diabetes Care Inc. Learn more here: https://www.pharmacytimes.org/on-demand/continuous-glucose-monitoring-understanding-the-pharmacists-role-in-patient-education-and-improving-outcomes-in-diabetes-management Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.  See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Continuous Glucose Monitoring:Understanding the Pharmacist's Role in Patient Education and Improving Outcomes in Diabetes Management   Objectives  Describe the use of continuous glucose monitoring (CGM) in diabetes management and ADA/AACE recommendations Recognize the role of the pharmacist in providing education related to the use of CGM devices and interpreting CGM data Faculty Disclosures Curtis L. Triplitt, PharmD, has the following relevant financial relationships with commercial interests to disclose: Consultant: Bayer Speaker's Bureau: Eli Lilly, NovoNordisk Susan Cornell, PharmD, CDCES, FAPhA, FADCES, has the following relevant financial relationships with commercial interests to disclose: Speaker's Bureau: Novo Nordisk, Inc. Other Support: Advanced Practitioner Advisory Board- Novo Nordisk, Inc. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for .5 contact hours of knowledge-based credit. This activity is supported by an independent educational grant from Abbott Diabetes Care Inc. Learn more here: https://www.pharmacytimes.org/on-demand/continuous-glucose-monitoring-understanding-the-pharmacists-role-in-patient-education-and-improving-outcomes-in-diabetes-management Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.  See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Continuous Glucose Monitoring:Understanding the Pharmacist’s Role in Patient Education and Improving Outcomes in Diabetes Management   Objectives  Describe the use of continuous glucose monitoring (CGM) in diabetes management and ADA/AACE recommendations Recognize the role of the pharmacist in providing education related to the use of CGM devices and interpreting CGM data Special Guests:  Susan Cornell, PharmD, CDCES, FAPhA, FADCES, Associate Director of Experiential Education and Associate Professor of the Department of Pharmacy Practice at Midwestern University Chicago College of Pharmacy in Downers Grove, Illinois. Curtis Triplitt, PharmD, CDCES, Clinical Associate Professor of Medicine for the Division of Diabetes at University of Texas Health Science Center at San Antonio and The Texas Diabetes Institute University Health System in San Antonio, Texas. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 5 contact hours of knowledge-based credit. This activity is supported by an independent educational grant from Abbott Diabetes Care Inc. See omnystudio.com/listener for privacy information.